GeNeuro Announces Approval of all Resolutions Proposed at 2023 Annual General Meeting

- 78.10% of the Company’s share capital was represented at the AGM and resolutions were all widely approved

Geneva, Switzerland, June 15, 2023 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of June 14, 2023. These included among others:

- Approval of the annual report and accounts for the year ended 31 December 2022
- Appropriation of reserves
- Re-election of the Chairman and all Members of the Board of Directors who were on the ballot
- Approval of maximum aggregate Board of Directors and Managerial compensation for 2024
- Re-election of PricewaterhouseCoopers, Geneva, as auditors
- Amendments to the articles of association, proposed in order to implement most of the provisions of the new Swiss Company law: approval of all proposals, notably the new capital band.

78.10% of the Company’s share capital was represented at the AGM and resolutions were all widely approved. Detailed results will be available on the Company’s website at: http://www.geneuro.com/en/investors/general-meetings.

About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has rights to 18 patent families protecting its technology.

For more information, visit: www.geneuro.com

Contacts:

GeNeuro
Jesus Martin-Garcia
Chairman and CEO
+41 22 552 48 00
investors@geneuro.com

NewCap (France)
Louis-Victor Delouvrier / Mathilde Bohin (investors)
+33 1 44 71 98 52
Arthur Rouillé (media)
+33 1 44 71 00 15
geneuro@newcap.eu
Disclaimer:

This press release contains certain forward-looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management’s current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.